Fast Five Quiz: Pulmonary Arterial Hypertension Treatment

Vikramjit Khangoora, MD


June 02, 2022

Clinical outcomes are significantly improved with the use of targeted therapy. The AMBITION clinical trial revealed that patients with PAH who had not received previous treatment may benefit from immediate combination therapy with a 50% relative risk reduction for time to clinical failure compared with patients on monotherapy. High-risk patients with PAH may benefit from combination triple therapy including prostacyclin. Combination therapy has been associated with a higher survival rate, particularly in younger patients.

Lung transplant is considered in patients with PAH who are refractory to treatments.

According to the updated American College of Chest Physicians (CHEST) guidelines, patients with PAH should be referred to palliative care. Along with disease-directed therapies, early management of the physical, psychosocial, and spiritual aspects of living with a chronic and life-limiting illness may be beneficial to patients.

Learn more about pulmonary arterial hypertension.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.